Development of a novel depot delivery system for a glaucoma therapeutic
开发用于青光眼治疗的新型储库递送系统
基本信息
- 批准号:10699791
- 负责人:
- 金额:$ 33.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultBackBiodistributionBiomedical EngineeringBlindnessCaringClinicClinicalCorneaDataDevelopmentDosage FormsDoseDropsEmulsionsEngineeringEyeEyedropsFDA approvedFamilyFormulationGenerationsGlaucomaGoalsHomeHourInjectionsLegal patentMarketingMechanicsPatientsPerformancePersonsPharmaceutical PreparationsPhasePhysiologic Intraocular PressurePhysiologicalPolymersPositioning AttributePreparationPrevalencePropertyResearchRisk FactorsSafetyScheduleSelf AdministrationSmall Business Innovation Research GrantSpecialistSystemTechnologyTestingTherapeuticTimeTopical applicationVisionVisual Fieldsbiocompatible polymerbiodegradable polymerbiomaterial compatibilitycommercializationcompliance behaviordesigndrug distributionexperienceinnovationirritationnanofibernegative affectnovelphase 1 studypre-Investigational New Drug meetingpregabalinpreservationpressureresidenceside effectstandard of caretherapy development
项目摘要
Glaucoma is the leading cause of irreversible blindness in the world. Because elevated intraocular pressure
(IOP) and IOP fluctuations are the primary risk factors for loss of visual field, the current standard of care
for adult-onset glaucoma includes treatment with IOP-lowering medications, which are typically delivered topically
as eye drops. Unfortunately, the need for self-administration negatively affects patient compliance. Moreover,
there are a limited number of drug families that are in use. In a major step toward addressing the limitations of
currently marketed IOP-lowering drops, we engineered a novel non-irritative microemulsion (ME) formulation that
provides extended release of pregabalin (PRG)¾a repurposed FDA-approved drug with a new mechanism of
action for IOP-lowering. While our ME has many features that position it to fill major gap in IOP management, it
requires daily self-dosing. To directly address this unmet clinical need, we will optimize and evaluate the
IOP-lowering properties and safety of a subconjunctival biodegradable electrospun depot containing
PRG. OculoTherapy’s long-term research goal is to develop therapies that preserve vision in glaucoma patients.
In this current SBIR Phase I application, we test the hypothesis that a subconjunctival depot comprised of slowly
biodegradable and biocompatible nanospun polymers can be engineered to provide zero order release of
PRG, which will maintain IOP in the physiological range until the depot is spent. Our objective is to ultimately
achieve 4 months of release from a single subconjunctival injection. Our hypothesis is supported
our preliminary data demonstrating that PRG-loaded nanofibers comprised of a polymeric blend provide release
of PRG with only 13% of loaded drug being released after 4 weeks, demonstrating that 4 months of release from
a single depot is well within range. Overall strengths of this project include: 1) a strong and experienced
interdisciplinary OculoTherapy team; 2) engineering of an innovative delivery strategy using a polymeric
biocompatible depot that is expected to provide extended drug release; 3) the use of a highly promising FDA-
approved drug that is being repurposed as a glaucoma therapeutic; and 4) the potential for a highly significant
increase in patient adherence because the need for daily input from the patient is eliminated. In this Phase I SBIR
proposal, we provide proof-of-concept data and address key feasibility questions by establishing the safety and
efficacy of a bioengineered subconjunctivally placed polymer depot. Aim 1: We test the hypothesis that a
subconjunctival electrospun depot comprised of biodegradable and biocompatible polymers can provide up to 4
months of zero order release of PRG. Several polymers and polymer blends will be evaluated either alone or in
combination. Aim 2: We test the hypothesis that our subconjunctival PRG depot is biocompatible and efficacious.
IOP and safety will be evaluated. Ocular biodistribution studies will also be performed. Minimum performance
metrics include: 1) a sustained decrease in IOP for ~4 months from a single depot; 2) no significant development
of tolerance; and 3) an intraocular distribution of the drug that correlates with its effect on IOP reduction.
青光眼是世界上不可逆性失明的主要原因。因为眼内压升高
(IOP)和IOP波动是视野丧失的主要危险因素,
成人型青光眼的治疗包括使用降低IOP的药物进行治疗,这些药物通常是局部给药
作为眼药水不幸的是,自我给药的需要对患者的依从性产生了负面影响。此外,委员会认为,
使用的药物种类有限。在解决限制的一个重要步骤中,
目前市售的降眼压滴剂,我们设计了一种新的无刺激性微乳液(ME)制剂,
提供普瑞巴林(PRG)的延长释放,这是一种重新利用的FDA批准的药物,具有以下新机制:
降低IOP的措施。虽然我们的ME具有许多功能,可以填补IOP管理的主要空白,
需要每天自我给药为了直接解决这一未满足的临床需求,我们将优化和评估
结膜下可生物降解的静电纺丝贮库的降IOP特性和安全性,
PRG。OculoTherapy的长期研究目标是开发保护青光眼患者视力的疗法。
在目前的SBIR I期应用中,我们测试了结膜下贮库由缓慢的
生物可降解和生物相容性的纳米纺聚合物可以被工程化以提供
PRG,其将IOP维持在生理范围内,直到储药耗尽。我们的目标是最终
实现从单次结膜下注射中释放4个月。我们的假设得到了支持
我们的初步数据表明,由聚合物共混物组成的载有PRG的纳米纤维提供释放,
的PRG,仅13%的负载药物在4周后释放,表明从PRG释放4个月,
只有一个仓库在射程内本项目的整体优势包括:1)实力雄厚,经验丰富
跨学科眼科治疗团队; 2)使用聚合物
预期提供延长的药物释放的生物相容性贮库; 3)使用非常有前途的FDA-
被批准的药物被重新用作青光眼治疗;和4)潜在的高度显着的
患者依从性的增加,因为消除了对来自患者的每日输入的需要。在本阶段I SBIR中,
建议,我们提供概念验证数据,并通过建立安全性和
生物工程结膜下放置的聚合物贮库的功效。目的1:我们测试假设,
由生物可降解和生物相容性聚合物组成的结膜下静电纺丝贮库可以提供高达4
几个月的零订单释放PRG。几种聚合物和聚合物共混物将单独或在
组合.目的2:我们检验我们的结膜下PRG贮库具有生物相容性和有效性的假设。
将评价IOP和安全性。还将进行眼部生物分布研究。最低性能
指标包括:1)单次储药后IOP持续降低约4个月; 2)无显著变化
耐受性;和3)与其对IOP降低的作用相关的药物的眼内分布。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dianna Ammons Johnson其他文献
Dianna Ammons Johnson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dianna Ammons Johnson', 18)}}的其他基金
Neuroprotective Properties of a Novel Glaucoma Drug and Formulation
新型青光眼药物和制剂的神经保护特性
- 批准号:
10254556 - 财政年份:2021
- 资助金额:
$ 33.6万 - 项目类别:
Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma
一种新型降眼压药物的缓释制剂,可改善青光眼的治疗
- 批准号:
10045373 - 财政年份:2019
- 资助金额:
$ 33.6万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 33.6万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 33.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 33.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 33.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)